Claims for Patent: 10,081,671

Summary for Patent: 10,081,671

Title:	Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV)
Abstract:	This invention is directed to an antibody construct or fragment thereof derived from an RSV-infected human, such that the antibody construct binds with specificity to RSV fusion protein antigenic region II/A with an affinity of greater than 1.times.10.sup.-9M. Preferably, the antibody construct is capable of neutralizing RSV strains, including at least one RSV strain that is resistant to palivizumab. The invention further relates to nucleic acids encoding the antibody construct or portions thereof, and cell lines expressing the antibody. This invention further relates to methods for producing said antibody construct, and to the use of said antibody construct for treating or preventing infection of a patient by RSV having a normal or mutated version of F protein.
Inventor(s):	Koch; Holger (San Jose, CA), Urwyler; Simon (San Jose, CA), Rudolf; Michael (San Jose, CA), Truong; Vu (Campbell, CA)
Assignee:
Application Number:	15/523,190
Patent Claims:	1. A cell comprising a first cDNA comprising a sequence which encodes a heavy chain variable region and a second cDNA comprising sequence which encodes a light chain variable region, wherein the cell produces an antibody construct or antibody fragment comprising the heavy chain variable region and the light chain variable region, wherein the heavy chain variable region encoded by the first cDNA sequence comprises (a) a heavy chain complementarity determining region (CDR) CDR1 comprising the amino acid sequence GASINLYD (SEQ ID NO.: 8), (b) a heavy chain CDR2 comprising the amino acid sequence GYISGST (SEQ ID NO.: 9), and (c) a heavy chain CDR3 comprising the amino acid sequence ARDVGWGPQYYYGLDV (SEQ ID NO.: 10); wherein the light chain variable region encoded by the second cDNA sequence comprises (a) a light chain CDR1 comprising the amino acid sequence HSVQSTS (SEQ ID NO.: 14), (b) a light chain CDR2 comprising the amino acid sequence GGS (SEQ ID NO.: 15), and (c) a light chain CDR3 comprising the amino acid sequence QQSDRSPPIT (SEQ ID NO.: 16); and, wherein the cell is other than a beta lymphocyte. 2. The cell of claim 1, wherein the cell is selected from the group consisting of: plant cells, Chinese hamster ovary (CHO) cells, and human embryonic kidney (HEK) cells. 3. The cell of claim 1, wherein the N-glycan is a non-human N-glycan. 4. The cell of claim 1, wherein the light chain and heavy chain CDR sequences originate from different beta lymphocytes. 5. The cell of claim 1, wherein the antibody construct or antibody fragment binds with specificity to RSV F protein antigenic region II/A with an affinity of greater than 1.times.10.sup.-9 M. 6. The cell of claim 1, wherein the antibody construct or antibody fragment is an IgG.sub.1. 7. The cell of claim 1, wherein the cell comprises one or more expression vectors, wherein the one or more expression vectors comprise the first cDNA sequence or the second cDNA sequence. 8. The cell of claim 1, wherein at least one expression vector is stably transfected into the cell and adapted to provide expression of the first cDNA sequence or the second cDNA sequence. 9. The cell of claim 1, wherein the heavy chain variable region cDNA sequence comprises the nucleotide sequence of SEQ ID NO: 2 or the light chain variable region cDNA sequence comprises the nucleotide sequence of SEQ ID NO: 4. 10. The cell of claim 1, wherein the light chain and heavy chain are from different antibodies produced by an RSV patient. 11. The cell of claim 1, wherein the antibody construct or antibody fragment neutralizes at least one RSV strain that is resistant to palivizumab. 12. The cell of claim 1, wherein the antibody or antibody fragment comprises glycans lacking fucose and xylose. 13. An antibody or antibody fragment comprising at least a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises (a) a heavy chain complementarity determining region (CDR) CDR1 comprising the amino acid sequence GASINLYD (SEQ ID NO.: 8), (b) a heavy chain CDR2 comprising the amino acid sequence GYISGST (SEQ ID NO.: 9), and (c) a heavy chain CDR3 comprising the amino acid sequence ARDVGWGPQYYYGLDV (SEQ ID NO.: 10); and wherein the light chain variable region comprises (a) a light chain CDR1 comprising the amino acid sequence HSVQSTS (SEQ ID NO.: 14), (b) a light chain CDR2 comprising the amino acid sequence GGS (SEQ ID NO.: 15), and (c) a light chain CDR3 comprising the amino acid sequence QQSDRSPPIT (SEQ ID NO.: 16), wherein the antibody or antibody fragment comprises glycans lacking fucose and xylose. 14. The antibody or antibody fragment of claim 13, wherein the glycans are non-human N-glycans. 15. The antibody or antibody fragment of claim 13, wherein the antibody construct or antibody fragment recognizes an epitope in a region of SEQ ID NO.: 23 or SEQ ID NO.: 24. 16. An expression vector comprising a first nucleic acid comprising a sequence which encodes a heavy chain variable region and a second nucleic acid comprising a sequence which encodes a light chain variable region, wherein the cell produces an antibody construct or antibody fragment comprising the heavy chain variable region and the light chain variable region, wherein the heavy chain variable region encoded by the first nucleic acid sequence comprises (a) a heavy chain complementarity determining region (CDR) CDR1 comprising the amino acid sequence GASINLYD (SEQ ID NO.: 8), (b) a heavy chain CDR2 comprising the amino acid sequence GYISGST (SEQ ID NO.: 9), and (c) a heavy chain CDR3 comprising the amino acid sequence ARDVGWGPQYYYGLDV (SEQ ID NO.: 10); and wherein the light chain variable region encoded by the second nucleic acid sequence comprises (a) a light chain CDR1 comprising the amino acid sequence HSVQSTS (SEQ ID NO.: 14), (b) a light chain CDR2 comprising the amino acid sequence GGS (SEQ ID NO.: 15), and (c) a light chain CDR3 comprising the amino acid sequence QQSDRSPPIT (SEQ ID NO.: 16). 17. The expression vector of claim 16, wherein the first nucleic acid or second nucleic acid is a cDNA or wherein the light chain and heavy chain CDR sequences originate from different beta lymphocytes.

Details for Patent 10,081,671

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998		2039-02-26
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	07/23/2004		2039-02-26